Capricor Therapeutics (CAPR) CFO Bergmann Sells 24,100 Shares

CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) on June 25, 2026. The sale was valued at approximately $76,638, based on an average price of $3.18 per share. This sale comes shortly after Bergmann also made a purchase of shares on the same day.

Inside Anthony Bergmann's Trade

Bergmann's sale adds to the recent activity among insiders at Capricor. His transaction aligns with a prior purchase of 24,100 shares on the same day, which signifies a notable shift in his investment posture. The shares sold at a time when the stock is trading at $23.80, reflecting a healthy interest in the company.

Other Institutional Activity in Capricor

Several other funds have been active with Capricor's stock. Blackrock Inc. increased its holdings by 723,350 shares, bringing its total to 4,145,061 shares worth about $27,958,435. Tang Capital Management also grew its position by 700,033 shares, ending with 4,099,900 shares valued at approximately $27,653,825. Meanwhile, State Street Corporation raised its stake by 1,215,294 shares, totaling 3,397,150 shares worth around $22,913,776.

Capricor Therapeutics, Inc. Stock Up 162.7%

As of the article's publication on June 25, 2026, Capricor's stock traded at $23.80. This price point is significantly higher than its 52-week low of $2.96, suggesting the stock has been on a promising upward trajectory lately. The shares are currently trading well above their 200-day average, which stands at about $23.53.

Recent Earnings

Capricor's next earnings report is scheduled for November 10, 2026. The company operates in the biotechnology sector, focusing on developing innovative therapies for Duchenne muscular dystrophy and other serious diseases. Recent earnings indicate it has not yet turned a profit, with an EPS of -$2.45.

Insider Buying and Selling at Capricor Therapeutics, Inc.

On June 25, 2026, besides Bergmann's sale, EVP Karen Krasney also sold 24,100 shares of Capricor. Krasney's sale was recorded at a price of $0, reflecting a disclosure requirement. Earlier, on June 22, both Bergmann and Krasney sold additional shares, indicating a trend in insider selling.

Analysts Set New Price Targets

Capricor has recently seen upgrades from analysts. On September 14, 2026, B. Riley Securities upgraded the stock to a Buy rating with a target of $21.00, significantly up from a prior target of $5.00. Piper Sandler also upgraded its rating to Overweight with a price target of $25.00.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm based in San Diego, California. The company is committed to creating innovative cell and exosome-based therapies aimed at treating Duchenne muscular dystrophy and similar conditions. Its leading product candidate, Deramiocel, is currently in a phase 3 clinical trial.

Bottom Line

Investors will be watching for Capricor's next earnings release on November 10, 2026. The recent insider activity, particularly by Bergmann, indicates ongoing engagement from management. As always, filings reflecting the past may not reflect current holdings.